Bicara Therapeutics Inc.

What they do

Bicara is developing ficerafusp alfa, formerly BCA101, a bifunctional EGFR-directed monoclonal antibody bound to a TGF-beta ligand trap, designed to deliver TGF-beta inhibition directly into the tumor microenvironment. The company has no approved products and no revenue; its operations consist of preclinical and clinical development. Its lead program is studied in head and neck squamous cell carcinoma, including the Phase 2/3 FORTIFI-HN01 pivotal trial.

Revenue drivers

• Ficerafusp alfa (pre-revenue) — Lead and only clinical program; no product revenue has been recognized to date, and any future revenue depends on regulatory approval and commercialization.
• 1L R/M HPV-negative HNSCC indication — Primary intended indication; the Phase 2/3 FORTIFI-HN01 trial is the basis for a potential accelerated approval and U.S. launch in 2028.
• Alternate dosing regimens — The FORTIFI-FLEX study evaluates a 12-week 1500mg weekly loading dose followed by 2250mg every three weeks, intended to expand optionality for patients and providers.
• Other squamous cell carcinomas (pipeline only) — EGFR and TGF-beta overexpression is cited for tumors such as cutaneous squamous cell carcinoma, anal squamous cell carcinoma and colorectal cancer, but no trials in these indications are described as ongoing.

Recent performance

Bicara reported a net loss of $137.9 million for 2025, compared with $68.0 million in 2024 and $52.0 million in 2023. Operating cash flow was negative $106.8 million in 2025, versus negative $74.8 million in 2024 and negative $45.6 million in 2023. Diluted EPS improved from negative $89.61 in 2023 to negative $4.05 in 2024 and negative $2.52 in 2025. At June 30, 2026, total assets were $512.2 million, total liabilities $43.5 million, shareholder equity $468.8 million, and cash and equivalents $96.6 million. The company announced in February 2026 that the transition to the Phase 3 portion of FORTIFI-HN01 was completed.

Strategy

Bicara is focused on developing ficerafusp alfa in tumor types with strong biologic rationale and inadequate tumor penetration, led by 1L R/M HPV-negative HNSCC. The Phase 2/3 FORTIFI-HN01 trial, evaluating 1500mg weekly plus pembrolizumab, is expected to be substantially enrolled by the end of 2026 to enable an interim analysis in mid-2027. The company initiated the FORTIFI-FLEX alternate dosing study in August 2026 to evaluate a weekly loading dose followed by every-three-week maintenance. Bicara announced leadership transitions effective January 2027, with Ryan Cohlhepp becoming CEO, Tanya Green becoming COO, Jenna Cohen becoming Chief Business Officer, Jenn Larson appointed CFO effective August 12, 2026, and Greg Shiferman appointed Chief Legal Officer effective August 31, 2026. Management states these changes are intended to support preparation for potential commercialization of ficerafusp alfa in 1L R/M HPV-negative HNSCC.

Risks

• Dependence on a single program — The business is highly dependent on ficerafusp alfa, and failure or delay in its development, approval or commercialization would materially harm the company.
• No revenue and continuing losses — The company has no approved products, has incurred significant losses since inception, and expects to continue incurring significant losses for the foreseeable future.
• Need for additional capital — If the company cannot raise capital when needed or on acceptable terms, it may be unable to complete development and commercialization of ficerafusp alfa.
• Clinical and regulatory uncertainty — Clinical development is lengthy, expensive and unpredictable, and the FDA and comparable foreign authorities may not approve the product candidates.

Outlook

Management expects substantial enrollment of the FORTIFI-HN01 pivotal trial by the end of 2026, enabling a topline interim analysis in mid-2027. The company states the interim analysis could support potential accelerated approval and a U.S. launch in 2028. The FORTIFI-FLEX alternate dosing study was initiated in August 2026, with results expected by the time of potential accelerated approval. Leadership transitions take effect in August 2026 and January 2027.